In the ever-changing territory of the pharmaceutical industry, API, as a key link in the industrial chain, its performance has always affected the nerves of the market.

Entering the midfield of 2024, the API industry ushered in a performance test. Those companies that have bucked the trend under the "growth haze" have become the focus of the industry.

In the first half of 2024, the API industry was clouding, and most companies experienced a decline in performance.

According to data from Flush I, in the first half of this year, of the 45 A- share API companies, only 16 achieved both total revenue and net profit growth, accounting for 35.56; on the contrary, 29 companies experienced negative growth (The growth rate of total revenue and net profit attributable to the parent company was negative, and one of them was negative), accounting for 64.44.
Judging from the overall performance, 11 companies have a total revenue of more than 1 billion yuan, of which Xincheng (9.845 billion yuan) is the highest, followed by Puluo Pharmaceutical (6.429 billion yuan); in addition, 13 companies have a net profit of more than 0.1 billion yuan, but only Xincheng has broken through the 1 billion mark, reaching 2.204 billion yuan. The 2. three are Chuanning Biology (0.766 billion yuan) and Puluo Pharmaceutical (0.625 billion yuan).
Among the 16 companies that achieved positive growth, 10 had a year-on-year increase in total revenue of more than 10%, and 4 had a year-on-year growth rate of more than 30%, namely Xinhe Hecheng, Orete, Chuanning Biology and Will Pharmaceutical. In terms of net profit attributable to the parent, 15 increased by more than 10% year-on-year, and 9 increased by more than 30%. Among them, Orete and Chuanning Biology both increased by more than 90% year, overflow and Hehua shares are as high as 464.1 per cent and 639.3 per cent, respectively.